IP Library Granted Patent US 8,088,884
Granted Patent B2
US 8,088,884 · App. 12/680,448 · Granted Jan 3, 2012

Multi-armed forms of activated polyoxazoline and methods of synthesis thereof

Assignee: Serina Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,884
App. No.
12/680,448
Granted
Jan 3, 2012
Kind
B2
Abstract

The present disclosure provides novel POZ-2 derivatives, methods for synthesizing POZ-2 derivatives and intermediates useful in such methods. In one embodiment, the POZ-2 derivative comprises two linear POZ chains of the present disclosure linked directly or indirectly to a branching moiety that contains a functional group for linking the POZ-2 derivative to the target molecule. Target molecule-POZ-2 conjugates are also described. In certain embodiment, the POZ-2 derivatives have low polydispersity values and a decreased amount of impurities produced by unwanted side reactions, such as, but not limited to, chain transfer.

Claims (31)

1. An activated polyoxazoline-2 (POZ-2) derivative of the general structure

Wherein

POZ a is a polyoxazoline of formula —[N(COR 2 )CH 2 CH 2 ] n —;

POZ b is a polyoxazoline of formula —[N(COR 2 )CH 2 CH 2 ] x —;

L(I), L(II) and L(III) are linking groups;

Br is a branching moiety that is linked with or without a linking group to POZ a , POZ b and is selected from the group consisting of a nitrogen atom, a substituted or unsubstituted aryl group or a carbon atom, provided that when Br is a carbon atom, at least one of c or d is 1 and the corresponding linking group contains a substituted or unsubstituted aryl group;

X is a functional group which is capable of forming a linkage with a target molecule or being converted to a group that is capable of forming a linkage with a target molecule;

A is a non-reactive group;

R 1 is independently selected for each of POZ a and POZ b from hydrogen, alkyl, substituted alkyl, aralkyl, or substituted aralkyl group;

R 2 is independently selected for each repeating unit of POZ from an unsubstituted or substituted alkyl, alkenyl, alkyl, aralkyl or aryl group;

c, d and e are independently selected from 1 or zero;

f is zero when Br is a nitrogen atom or substituted or unsubstituted aryl group and is 1 when Br is a carbon atom; and

n and x are independently selected for each of POZ a and POZ b from 3 to 1000.

2. The POZ-2 derivative of claim 1 wherein R 2 has from 1 to 12 carbon atoms.

3. The POZ-2 derivative of claim 1 wherein R 2 is methyl, ethyl or n-propyl.

4. The POZ-2 derivative of claim 1 wherein at least one of POZ a and POZ b of the POZ-2 derivative has a polydispersity value of less than or equal to 1.2, less than or equal to 1.1 or less than or equal to 1.05.

5. The POZ-2 derivative of claim 1 wherein the POZ-2 derivative is a monofunctional POZ-2 derivative.

6. The POZ-2 derivative of claim 1 wherein X is selected from the groups consisting of carboxylic acid, active esters, carbonates, aldehyde, oxyamine, acetylene, isocyanates, isothiocyanate, amines, alcohol, tresylate (2,2,2-trifluorethylsulfonate), vinylsulfone, iodoacetamide, pyridyldisulfide, ketones, azide, hydrazide and maleimide.

7. The POZ-2 derivative of claim 1 wherein the linkage with the target molecule is a hydrolytically stable linkage.

8. The POZ-2 derivative of claim 1 wherein the functional group is protected.

9. The POZ-2 derivative of claim 1 wherein L(I), L(II) and L(III) are each independently selected from —NH—, substituted or unsubstituted alkyl groups or substituted or unsubstituted alkenyl groups.

10. The POZ-2 derivative of claim 1 wherein A is H or a substituted or unsubstituted alkyl group.

11. The POZ derivative of claim 1 wherein Br is a C atom and c is 1 and L(I) contains a substituted or unsubstituted aryl group.

12. The POZ derivative of claim 1 wherein Br is a C atom and c is 1, d is 1 and at least one of L(I) and L(II) contains a substituted or unsubstituted aryl group.

13. A target molecule-POZ-2 conjugate of the general formula A-B-TM, wherein

A is a POZ-2 derivative of claim 1 minus any leaving groups eliminated during the reaction of the active functional group on the POZ-2 derivative with a binding partner on a target molecule;

TM is a target molecule, the target molecule containing the binding partner; and

B is a hydrolytically stable linkage formed between the active functional group and the binding partner.

14. The target molecule-POZ-2 conjugate of claim 13 wherein the active functional group is an Iodoacetamide, the binding partner is SH and B is a thioether linkage, the active functional group is a maleimide, the binding partner is SH and B is a thioether linkage, the active functional group is an active carbonate, the binding partner is NH 2 and B is a urethane linkage, the active functional group is an active ester, the binding partner is NH 2 and B is an amide linkage or the active functional group is an aldehyde, the binding partner is NH 2 and B is an amine linkage.

15. The target molecule POZ-2 conjugate of claim 13 wherein the in vivo half-life of the target molecule-POZ-2 conjugate is increased under physiological conditions.

16. The target molecule POZ-2 conjugate of claim 13 wherein at least one POZ chain of the POZ-2 derivative has a polydispersity value of less than or equal to 1.2, less than or equal to 1.1 or less than or equal to 1.05.

Assignments (2)
CHANGE OF NAME Recorded Apr 9, 2024
From: SERINA THERAPEUTICS, INC.
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 067050/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2010
From: HARRIS, J MILTON; BENTLEY, MICHAEL DAVID; YOON, KUNSANG; FANG, ZHIHAO
To: SERINA THERAPEUTICS, INC.
Reel/Frame 024295/0625 →
Continuity (2)
Provisional Application 60975808 · Sep 27, 2007
Related Publication 20100249368A1 · Sep 30, 2010